Enzalutamide, an androgen receptor signaling inhibitor, is a standard of care treatment for metastatic castration-resistant prostate cancer. We present the first reported case of enzalutamide in a patient with end-stage renal disease, on dialysis. While there were no significant toxicities, a sustained increase in systolic blood pressure was maintained after starting enzalutamide, suggestive of a degree of drug accumulation. Further evaluation of novel hormonal agents in end-stage renal disease patients should be encouraged as this population is typically excluded from clinical trials.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2017 Jan 01 [Epub ahead of print]
Erica S Tsang, Marie de Haan, Bernhard J Eigl
Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada.